Leonard Bell, Alexion Pharmaceuticals

Co-Founder, Chairman and CEO (retired as CEO as of April 1), Alexion Pharmaceuticals
Total 2014 Compensation: $20.57 million

Until April, Leonard Bell was the only CEO Alexion Pharmaceuticals ($ALXN) ever had. Now upstairs in the chairman's seat, Bell ended his tenure as CEO on a high note, with $20.57 million in total compensation--a nice jump from the $13 million-plus he earned for 2013.

That breaks down to $1.28 million in base salary, plus another $2.03 million in incentive pay. Bell's stock awards amounted to $8.17 million, and his option awards were valued at $9.07 million. Some $23,000 in perks and other benefits rounded out the total.

Bell's compensation package may have grown by about 50%, but Alexion's sales took a leap upward, too--if not quite as big a leap. The company posted a 44% increase in 2014 sales, to $2.23 billion, with $2.15 billion of that from its rare disease treatment Soliris. That drug has been Alexion's sole marketed product for years, but 2014 also marked regulatory submissions for Strensiq (astofase alfa), which treats a rare bone condition.

An FDA-designated orphan drug, Strensiq is waiting for U.S. approval, but it's now cleared for sale in Japan, and it won backing from European regulators at the end of June. The company also won European backing for Kanuma, an enzyme replacement therapy it picked up in its $8.4 billion buyout of Synageva.

Alexion COO David Hallal took the reins as CEO on April 1.

For more:
Special Report: 15 Highest-Paid Biopharma CEOs of 2013 - Leonard Bell
Lonza expands New Hampshire plant to make Alexion products
Alexion wins EMA nods for not one but two drugs
Alexion names David Hallal its next CEO
Leaping Soliris sales send Alexion's bottom line soaring

Leonard Bell, Alexion Pharmaceuticals

Suggested Articles

The efficacy between Keytruda and FerGene's nadofaragene firadenovec look comparable in their studies, though Merck has at least one upper hand.

Thursday, the FDA approved the first three generic versions of Gilenya, but they may not hit the market anytime soon due to ongoing litigation.

Gilead is hoping to score a patent extension on TAF meds, but patient advocates say that would reward conduct that harmed patients.